DNA Script Wins the Grand Prize Trophy at the 2022 French Future Unicorns Ceremony
DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, won the Grand Prize Trophy at the 2022 Future Unicorns Awards, whose ceremony took place on September 15, 2022, at the Bourrienne Hotel (Paris). Of the 1400 French companies initially identified for consideration, a jury narrowed them down to 250 that met the criteria, from which DNA Script was selected as the Grand Prize winner.
"DNA Script is honored to receive the Grand Prize Trophy, which recognizes our business and innovation strategy. Biology holds such incredible promise to solve some of mankind’s biggest challenges, with applications not just across healthcare but also climate change, food and clean water supply, bio-engineered materials and environmentally friendly chemicals, DNA data storage, and so much more. DNA Script’s mission is to make it easy for researchers to print DNA to accelerate this scientific discovery and the coming bio-revolution,” said Xavier Godron, DNA Script co-founder and CTO, in accepting the award on behalf of the company and his co-founders Thomas Ybert, CEO, and Sylvain Gariel, COO. “We share this award with the entire DNA Script team, who invest in the company's success daily; with our investors, who have placed their trust in us since the company’s inception; and with our customers, who share our vision to accelerate discovery through direct access to in-house DNA printing. We thank the members of the jury as well as their partners Audacia, Caisse d'Epargne, Deloitte, Emlyon Business School, Euronext, Reputation Age and Scope Group for this distinction."
DNA Script won the Biotech and Medtech Future Unicorns Award in 2021, and since then has achieved several milestones. These include completing a $200 million Series C investment round and expanding its global presence in China, Hong Kong, India, Singapore, South Korea and Taiwan for the sale, distribution and support of its products through distribution agreements. Following the launch of the SYNTAX System, the first commercial product using Enzymatic DNA Synthesis targeted at genomics and molecular biology workflows, in 2021, the company continues to develop their technology and portfolio of products to address DNA supply bottlenecks in life science research, precision therapeutics, biodefense, clinical testing and DNA data storage. The company launched new products earlier this year that enable researchers to develop much more efficiently new diagnostic or research assays, for instance in infectious diseases, personalized oncology fields or spatial biology. Recently the company announced a continued collaboration with the French Defense Innovation Agency, in liaison with the French Armament General Directorate (DGA), to detect and diagnose new pathogens. This collaboration followed a disclosed partnership with Wellcome Leap to accelerate the development of RNA-based products, including messenger RNA vaccines.
The Future Unicorns Trophies aim to identify French companies with strong growth potential that in the next five years can be valued at more than €1 billion. Five sectors are studied, and seven prizes are awarded: BioTech and MedTech, e-Commerce and Advertising, GreenTech and Mobility, Industry 4.0 and SaaS, and AI and Big Data. The selected companies must meet various criteria, including having their headquarters in France, being <15 years old, having raised >€5 million since company inception and being an unlisted independent company, among others.
About DNA Script
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005403/en/
Contact information
DNA Script Contact
Joleen Rau
joleen.rau@dnascript.co
publicrelations@dnascript.co
Press Contacts in the US
Seismic
Valerie Enes
415-692-6799
valerie@teamseismic.com
Press Contact in Europe
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 03:40:00 EET | Press release
Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge formats designed for different group styles and expectat
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 02:00:00 EET | Press release
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helical Fusion will further accelerate development under its flagship program, the Helix Program—a comprehensive roadmap to achieve the world’s first commercially viable fu
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Xsolla Integrates MVola as a Payment Method to Enable Instant, Card-Free Payments for Gamers in Madagascar’s Mobile-First Market4.12.2025 22:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced that MVola, Madagascar’s number one digital wallet, is now available as a payment option for players across the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204268075/en/ Chris Hewish, President of Xsolla Madagascar is a fast-growing, mobile-first market of 32 million people, where digital wallets are the primary driver of daily transactions. MVola, recently licensed as a digital bank, has established itself as the leading wallet in the country, with over 10 million users and powering more than 1 billion transactions annually. By adding MVola as a payment method to its portfolio, Xsolla removes the friction of card payments, enabling players to pay seamlessly with a trusted local method they already know and use every day. Key benefits of the MVola integration include: Instant confirmations
Board Recognized as a Leader in the Gartner ® Magic Quadrant™ for Financial Planning Software for Fourth Consecutive Year4.12.2025 19:14:00 EET | Press release
Board, the leading Enterprise Planning Platform, today announced that it has been named a Leaderin the2025 Gartner® Magic Quadrant™ for Financial Planning Software. This marks the fourth consecutive year the company has been positioned in the Leaders quadrant. The Board Enterprise Planning Platform integrates planning processes across the enterprise, enabling strategic, financial, and operational planning with near-real-time analysis and data sharing. Board’s unified approach to planning has driven strong adoption across financial and operational planning in the manufacturing, consumer packaged goods (CPG) and retail sectors. “We are proud to once again be named a Leader in the Gartner Magic Quadrant for Financial Planning Software,” said Jeff Casale, CEO of Board. “To Board, this recognition reflects our continued commitment to helping organizations unify strategic, financial, and operational planning within a single platform, and empower teams to plan continuously, make confident dec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom